NCT02245256View on ClinicalTrials.gov

Efficacy of Low-dose Dexmedetomidine to Prevent Delirium in Liver Transplant Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

217

Participants

Timeline

Start Date

September 1, 2014

Primary Completion Date

January 1, 2018

Study Completion Date

February 1, 2018

Conditions
Liver Transplantation
Interventions
DRUG

Precedex

infusion of 0.1mcg/kg/hr of precedex

DRUG

placebo control

placebo

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

All Listed Sponsors
collaborator

Hospira, now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

Seoul National University Hospital

OTHER

NCT02245256 - Efficacy of Low-dose Dexmedetomidine to Prevent Delirium in Liver Transplant Patients | Biotech Hunter | Biotech Hunter